Adaptive and Innate Immunity Are Key Drivers of Age at Onset of Multiple Sclerosis.

IF 3 3区 医学 Q2 CLINICAL NEUROLOGY
Neurology-Genetics Pub Date : 2024-05-29 eCollection Date: 2024-06-01 DOI:10.1212/NXG.0000000000200159
Elina Misicka, Yunfeng Huang, Stephanie Loomis, Nilanjana Sadhu, Elizabeth Fisher, Arie Gafson, Heiko Runz, Ellen Tsai, Xiaoming Jia, Ann Herman, Paola G Bronson, Tushar Bhangale, Farren B Briggs
{"title":"Adaptive and Innate Immunity Are Key Drivers of Age at Onset of Multiple Sclerosis.","authors":"Elina Misicka, Yunfeng Huang, Stephanie Loomis, Nilanjana Sadhu, Elizabeth Fisher, Arie Gafson, Heiko Runz, Ellen Tsai, Xiaoming Jia, Ann Herman, Paola G Bronson, Tushar Bhangale, Farren B Briggs","doi":"10.1212/NXG.0000000000200159","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Multiple sclerosis (MS) age at onset (AAO) is a clinical predictor of long-term disease outcomes, independent of disease duration. Little is known about the genetic and biological mechanisms underlying age of first symptoms. We conducted a genome-wide association study (GWAS) to investigate associations between individual genetic variation and the MS AAO phenotype.</p><p><strong>Methods: </strong>The study population was comprised participants with MS in 6 clinical trials: ADVANCE (N = 655; relapsing-remitting [RR] MS), ASCEND (N = 555; secondary-progressive [SP] MS), DECIDE (N = 1,017; RRMS), OPERA1 (N = 581; RRMS), OPERA2 (N = 577; RRMS), and ORATORIO (N = 529; primary-progressive [PP] MS). Altogether, 3,905 persons with MS of European ancestry were analyzed. GWAS were conducted for MS AAO in each trial using linear additive models controlling for sex and 10 principal components. Resultant summary statistics across the 6 trials were then meta-analyzed, for a total of 8.3 × 10<sup>-6</sup> single nucleotide polymorphisms (SNPs) across all trials after quality control and filtering for heterogeneity. Gene-based tests of associations, pathway enrichment analyses, and Mendelian randomization analyses for select exposures were also performed.</p><p><strong>Results: </strong>Four lead SNPs within 2 loci were identified (<i>p</i> < 5 × 10<sup>-8</sup>), including a) 3 SNPs in the major histocompatibility complex and their effects were independent of <i>HLA-DRB1*15:01</i> and b) a <i>LOC105375167</i> variant on chromosome 7. At the gene level, the top association was <i>HLA-C</i> (<i>p</i> = 1.2 × 10<sup>-7</sup>), which plays an important role in antiviral immunity. Functional annotation revealed the enrichment of pathways related to T-cell receptor signaling, autoimmunity, and the complement cascade. Mendelian randomization analyses suggested a link between both earlier age at puberty and shorter telomere length and earlier AAO, while there was no evidence for a role for either body mass index or vitamin D levels.</p><p><strong>Discussion: </strong>Two genetic loci associated with MS AAO were identified, and functional annotation demonstrated an enrichment of genes involved in adaptive and complement immunity. There was also evidence supporting a link with age at puberty and telomere length. The findings suggest that AAO in MS is multifactorial, and the factors driving onset of symptoms overlap with those influencing MS risk.</p>","PeriodicalId":48613,"journal":{"name":"Neurology-Genetics","volume":"10 3","pages":"e200159"},"PeriodicalIF":3.0000,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11139017/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology-Genetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/NXG.0000000000200159","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: Multiple sclerosis (MS) age at onset (AAO) is a clinical predictor of long-term disease outcomes, independent of disease duration. Little is known about the genetic and biological mechanisms underlying age of first symptoms. We conducted a genome-wide association study (GWAS) to investigate associations between individual genetic variation and the MS AAO phenotype.

Methods: The study population was comprised participants with MS in 6 clinical trials: ADVANCE (N = 655; relapsing-remitting [RR] MS), ASCEND (N = 555; secondary-progressive [SP] MS), DECIDE (N = 1,017; RRMS), OPERA1 (N = 581; RRMS), OPERA2 (N = 577; RRMS), and ORATORIO (N = 529; primary-progressive [PP] MS). Altogether, 3,905 persons with MS of European ancestry were analyzed. GWAS were conducted for MS AAO in each trial using linear additive models controlling for sex and 10 principal components. Resultant summary statistics across the 6 trials were then meta-analyzed, for a total of 8.3 × 10-6 single nucleotide polymorphisms (SNPs) across all trials after quality control and filtering for heterogeneity. Gene-based tests of associations, pathway enrichment analyses, and Mendelian randomization analyses for select exposures were also performed.

Results: Four lead SNPs within 2 loci were identified (p < 5 × 10-8), including a) 3 SNPs in the major histocompatibility complex and their effects were independent of HLA-DRB1*15:01 and b) a LOC105375167 variant on chromosome 7. At the gene level, the top association was HLA-C (p = 1.2 × 10-7), which plays an important role in antiviral immunity. Functional annotation revealed the enrichment of pathways related to T-cell receptor signaling, autoimmunity, and the complement cascade. Mendelian randomization analyses suggested a link between both earlier age at puberty and shorter telomere length and earlier AAO, while there was no evidence for a role for either body mass index or vitamin D levels.

Discussion: Two genetic loci associated with MS AAO were identified, and functional annotation demonstrated an enrichment of genes involved in adaptive and complement immunity. There was also evidence supporting a link with age at puberty and telomere length. The findings suggest that AAO in MS is multifactorial, and the factors driving onset of symptoms overlap with those influencing MS risk.

适应性免疫和先天性免疫是多发性硬化症发病年龄的关键因素。
背景和目的:多发性硬化症(MS)的发病年龄(AAO)是预测长期疾病结果的临床指标,与病程无关。人们对首次出现症状年龄的遗传和生物学机制知之甚少。我们开展了一项全基因组关联研究(GWAS),调查个体遗传变异与多发性硬化症 AAO 表型之间的关联:研究人群包括 6 项临床试验中的 MS 患者:ADVANCE(N = 655;复发缓解型[RR] MS)、ASCEND(N = 555;继发性进展型[SP] MS)、DECIDE(N = 1,017;RRMS)、OPERA1(N = 581;RRMS)、OPERA2(N = 577;RRMS)和ORATORIO(N = 529;原发性进展型[PP] MS)。总共对 3905 名欧洲血统的 MS 患者进行了分析。在每项试验中,利用控制性别和 10 个主成分的线性相加模型对 MS AAO 进行了遗传基因分析。然后对 6 项试验的汇总统计结果进行元分析,经过质量控制和异质性过滤后,所有试验中的单核苷酸多态性(SNPs)总数为 8.3 × 10-6。此外,还进行了基于基因的关联测试、通路富集分析和选定暴露的孟德尔随机分析:结果:在 2 个基因位点上发现了 4 个前导 SNPs(p < 5 × 10-8),包括 a) 主要组织相容性复合体中的 3 个 SNPs,其影响独立于 HLA-DRB1*15:01 和 b) 7 号染色体上的 LOC105375167 变异。在基因水平上,关联度最高的是在抗病毒免疫中发挥重要作用的 HLA-C(p = 1.2 × 10-7)。功能注释显示,与 T 细胞受体信号转导、自身免疫和补体级联相关的通路得到了丰富。孟德尔随机分析表明,青春期年龄提前、端粒长度缩短与AAO的发生时间提前之间存在联系,但没有证据表明体重指数或维生素D水平在其中起作用:讨论:发现了两个与多发性硬化症 AAO 相关的基因位点,功能注释显示,涉及适应性免疫和补体免疫的基因丰富。还有证据支持该基因与青春期年龄和端粒长度有关。研究结果表明,多发性硬化症的 AAO 是多因素的,导致症状出现的因素与影响多发性硬化症风险的因素重叠。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neurology-Genetics
Neurology-Genetics Medicine-Neurology (clinical)
CiteScore
6.30
自引率
3.20%
发文量
107
审稿时长
15 weeks
期刊介绍: Neurology: Genetics is an online open access journal publishing peer-reviewed reports in the field of neurogenetics. Original articles in all areas of neurogenetics will be published including rare and common genetic variation, genotype-phenotype correlations, outlier phenotypes as a result of mutations in known disease-genes, and genetic variations with a putative link to diseases. This will include studies reporting on genetic disease risk and pharmacogenomics. In addition, Neurology: Genetics will publish results of gene-based clinical trials (viral, ASO, etc.). Genetically engineered model systems are not a primary focus of Neurology: Genetics, but studies using model systems for treatment trials are welcome, including well-powered studies reporting negative results.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信